Close



Mar 10, 2024 04:05PM
Mar 10, 2024 04:05PM
Mar 4, 2024 08:00AM
Feb 29, 2024 10:19AM
Feb 29, 2024 07:30AM
Feb 27, 2024 04:11PM
Feb 27, 2024 04:08PM Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Feb 13, 2024 07:00AM
Feb 5, 2024 04:46PM
Feb 5, 2024 04:46PM
Jan 8, 2024 08:31AM
Jan 8, 2024 08:30AM
Dec 10, 2023 05:00PM
Nov 21, 2023 05:07AM Goldman Sachs Downgrades Incyte (INCY) to Neutral
Nov 2, 2023 09:00AM
Oct 31, 2023 07:00AM
Oct 16, 2023 08:00AM
Oct 13, 2023 10:31AM
Oct 13, 2023 10:30AM
Oct 13, 2023 08:00AM
Oct 12, 2023 09:00AM Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
Oct 11, 2023 10:30AM
Oct 11, 2023 09:15AM
Oct 11, 2023 08:15AM
Oct 11, 2023 08:15AM
Oct 10, 2023 04:45PM
Sep 29, 2023 01:43PM
Sep 18, 2023 09:18AM Incyte (INCY) falls as GSK wins approval for Ojjaara
Aug 1, 2023 07:00AM
Jul 24, 2023 07:02AM
Jul 24, 2023 07:00AM
Jul 11, 2023 04:06PM
Jul 11, 2023 04:05PM
Jun 27, 2023 04:00PM
May 25, 2023 05:01PM Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
May 2, 2023 08:00AM
May 2, 2023 07:00AM
May 1, 2023 03:00PM
May 1, 2023 03:00PM
Apr 16, 2023 03:01PM
Mar 27, 2023 05:48AM
Mar 27, 2023 02:00AM Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
Mar 24, 2023 05:55AM
Mar 23, 2023 08:55PM
Mar 22, 2023 01:14PM
Mar 22, 2023 01:14PM
Mar 20, 2023 05:56AM
Mar 19, 2023 06:45AM
Mar 18, 2023 03:40PM Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
Mar 18, 2023 10:40AM

251,412 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All